Regeneron Pharmaceuticals... (REGN)
Regeneron Pharmaceuticals Statistics
Share Statistics
Regeneron Pharmaceuticals has 107.51M shares outstanding. The number of shares has increased by 0.12% in one year.
| Shares Outstanding | 107.51M |
| Shares Change (YoY) | 0.12% |
| Shares Change (QoQ) | -0.32% |
| Owned by Institutions (%) | 85.82% |
| Shares Floating | 105.41M |
| Failed to Deliver (FTD) Shares | 109 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.12M, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 2.12M |
| Short % of Shares Out | 1.96% |
| Short % of Float | 2% |
| Short Ratio (days to cover) | 2.48 |
Valuation Ratios
The PE ratio is 17.42 and the forward PE ratio is 15.46. Regeneron Pharmaceuticals's PEG ratio is 1.68.
| PE Ratio | 17.42 |
| Forward PE | 15.46 |
| PS Ratio | 5.41 |
| Forward PS | 3.9 |
| PB Ratio | 2.62 |
| P/FCF Ratio | 20.97 |
| PEG Ratio | 1.68 |
Enterprise Valuation
Regeneron Pharmaceuticals Inc. has an Enterprise Value (EV) of 93.69B.
| EV / Earnings | 21.23 |
| EV / Sales | 6.6 |
| EV / EBITDA | 17.62 |
| EV / EBIT | 23.48 |
| EV / FCF | 25.57 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.73 |
| Quick Ratio | 3.95 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8.44 |
| Cash Flow / Debt | 1.63 |
| Interest Coverage | 72.3 |
Financial Efficiency
Return on equity (ROE) is 0.15% and return on capital (ROIC) is 11.49%.
| Return on Equity (ROE) | 0.15% |
| Return on Assets (ROA) | 0.12% |
| Return on Capital (ROIC) | 11.49% |
| Revenue Per Employee | $940,156.23 |
| Profits Per Employee | $292,109.1 |
| Employee Count | 15,106 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.64 |
Taxes
| Income Tax | 367.3M |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by -28.88% in the last 52 weeks. The beta is 0.08, so Regeneron Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.08 |
| 52-Week Price Change | -28.88% |
| 50-Day Moving Average | 699.99 |
| 200-Day Moving Average | 926.82 |
| Relative Strength Index (RSI) | 50.2 |
| Average Volume (20 Days) | 886.1K |
Income Statement
In the last 12 months, Regeneron Pharmaceuticals had revenue of 14.2B and earned 4.41B in profits. Earnings per share was 40.9.
| Revenue | 14.2B |
| Gross Profit | 12.23B |
| Operating Income | 3.99B |
| Net Income | 4.41B |
| EBITDA | 5.32B |
| EBIT | 3.99B |
| Earnings Per Share (EPS) | 40.9 |
Balance Sheet
The company has 2.49B in cash and 2.7B in debt, giving a net cash position of -216.2M.
| Cash & Cash Equivalents | 2.49B |
| Total Debt | 2.7B |
| Net Cash | -216.2M |
| Retained Earnings | 31.67B |
| Total Assets | 37.76B |
| Working Capital | 26.4B |
Cash Flow
In the last 12 months, operating cash flow was 4.42B and capital expenditures -755.9M, giving a free cash flow of 3.66B.
| Operating Cash Flow | 4.42B |
| Capital Expenditures | -755.9M |
| Free Cash Flow | 3.66B |
| FCF Per Share | 33.96 |
Margins
Gross margin is 86.13%, with operating and profit margins of 28.1% and 31.07%.
| Gross Margin | 86.13% |
| Operating Margin | 28.1% |
| Pretax Margin | 33.66% |
| Profit Margin | 31.07% |
| EBITDA Margin | 37.45% |
| EBIT Margin | 28.1% |
| FCF Margin | 25.8% |
Dividends & Yields
REGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.85% |
| FCF Yield | 4.88% |
Analyst Forecast
The average price target for REGN is $1065, which is 52.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $1065 |
| Price Target Difference | 52.4% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
Scores
| Altman Z-Score | 17.89 |
| Piotroski F-Score | 6 |